NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free PYXS Stock Alerts $4.30 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.25▼$4.4250-Day Range$3.65▼$6.5952-Week Range$1.35▼$6.85Volume164,540 shsAverage Volume649,712 shsMarket Capitalization$249.96 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Pyxis Oncology alerts: Email Address Pyxis Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.7% Upside$8.50 Price TargetShort InterestHealthy4.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector577th out of 915 stocksPharmaceutical Preparations Industry255th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingPyxis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePyxis Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.78% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pyxis Oncology has recently decreased by 18.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYXS. Previous Next 2.8 News and Social Media Coverage News SentimentPyxis Oncology has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pyxis Oncology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Pyxis Oncology is held by insiders.Percentage Held by InstitutionsOnly 39.09% of the stock of Pyxis Oncology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pyxis Oncology are expected to decrease in the coming year, from ($0.85) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Pyxis Oncology Stock (NASDAQ:PYXS)Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More PYXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYXS Stock News HeadlinesApril 14, 2024 | finance.yahoo.comPYXS Oct 2024 10.000 callApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic PotentialApril 28, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 3, 2024 | msn.comWhy Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMarch 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)March 28, 2024 | seekingalpha.comPyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The WaitMarch 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024April 28, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 27, 2024 | msn.comPyxis Oncology gets $8M payment for sale pf royalty rightsMarch 27, 2024 | globenewswire.comPyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic PotentialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial ProspectsMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster OptimismMarch 21, 2024 | marketwatch.comPyxis Oncology Shares Fall 10% After Apparent Delay in ResultsMarch 21, 2024 | investorplace.comPYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023March 21, 2024 | benzinga.comPyxis Oncology: Q4 Earnings InsightsMarch 21, 2024 | finance.yahoo.comPyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial ChallengesMarch 21, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023March 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 19, 2024 | markets.businessinsider.comPyxis Oncology (PYXS) Receives a Buy from Leerink PartnersMarch 17, 2024 | finance.yahoo.comPYXS Apr 2024 10.000 callMarch 17, 2024 | finance.yahoo.comPYXS Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comPYXS Jul 2024 7.500 callMarch 13, 2024 | globenewswire.comPyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFAMarch 7, 2024 | globenewswire.comPyxis Oncology to Present at Leerink Global Biopharma Conference 2024March 5, 2024 | globenewswire.comPyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingSee More Headlines Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PYXS CUSIPN/A CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+97.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.60% Return on Assets-41.08% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio4.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book1.53Miscellaneous Outstanding Shares58,130,000Free Float53,250,000Market Cap$249.96 million OptionableOptionable Beta1.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. John L. Flavin M.B.A. (Age 53)MBA, Ph.D., Co-Founder & Independent Chairman Comp: $87.5kDr. Lara S. Sullivan M.D.MBA, CEO, President & DirectorMs. Pamela Yanchik Connealy M.B.A. (Age 62)CFO & COO Comp: $709.7kMr. Ken Kobayashi FACP (Age 63)M.D., Chief Medical Officer Comp: $314.08kMr. Jitendra Wadhane (Age 43)Chief Accounting Officer, Senior VP of Finance & Corporate Controller Dr. Balu N. Balasubramanian Ph.D.Interim Chief Technology OfficerDr. Jan Pinkas Ph.D.Chief Scientific OfficerDr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRInozyme PharmaNASDAQ:INZYXeris BiopharmaNASDAQ:XERSNanobiotixNASDAQ:NBTXXBiotechNASDAQ:XBITView All CompetitorsInsiders & InstitutionsCable Car Capital LLCBought 61,606 shares on 2/20/2024Ownership: 0.139%Vestal Point Capital LPBought 440,000 shares on 2/14/2024Ownership: 0.993%Decheng Capital LLCBought 326,810 shares on 2/12/2024Ownership: 0.737%abrdn plcBought 708,303 shares on 1/31/2024Ownership: 1.598%Pamela Ann ConnealyBought 6,426 shares on 9/27/2023Total: $11,888.10 ($1.85/share)View All Insider TransactionsView All Institutional Transactions PYXS Stock Analysis - Frequently Asked Questions Should I buy or sell Pyxis Oncology stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PYXS shares. View PYXS analyst ratings or view top-rated stocks. What is Pyxis Oncology's stock price target for 2024? 6 brokers have issued twelve-month price targets for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $12.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 97.7% from the stock's current price. View analysts price targets for PYXS or view top-rated stocks among Wall Street analysts. How have PYXS shares performed in 2024? Pyxis Oncology's stock was trading at $1.80 at the beginning of the year. Since then, PYXS shares have increased by 138.9% and is now trading at $4.30. View the best growth stocks for 2024 here. Are investors shorting Pyxis Oncology? Pyxis Oncology saw a drop in short interest in April. As of April 15th, there was short interest totaling 2,210,000 shares, a drop of 18.1% from the March 31st total of 2,700,000 shares. Based on an average daily volume of 909,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.8% of the company's stock are sold short. View Pyxis Oncology's Short Interest. When is Pyxis Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PYXS earnings forecast. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.16. What ETF holds Pyxis Oncology's stock? Tema Oncology ETF holds 16,238 shares of PYXS stock, representing 0.43% of its portfolio. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYXS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
